Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OriginCell

Explore full profile

A biomedical equipment enterprise that develops tumor immuno-therapy solutions

Tangshan City, ChinaFounded 2014Biotech & Life Sciences
Valuation $250–500M Last recorded · 2022
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for OriginCell and the history behind them.

About OriginCell

Shanghai OriginCell Biological Cryo Equipment Co., Ltd. operates as a specialized subsidiary of the OriginCell Technology Group, focusing on the biomedical equipment sector. The company was established in 2017, incubated by its parent group, which was co-founded in 2014 by veteran entrepreneur Mr. Qu Jianguo and the publicly listed company Canature Health (300272). Mr. Qu, a notable figure who has successfully founded two other listed companies, serves as the Chairman and Chief Engineer of OriginCell, channeling his extensive entrepreneurial experience into the life sciences field. His journey began with founding a township enterprise in 1973 and later establishing 'Shenhua Industrial', one of the first eight companies listed on the A-share market. In 2014, he ventured into the health industry by founding the OriginCell Technology Group.

Read full description

The firm's core business revolves around the research, development, design, and manufacturing of advanced automated cryogenic storage equipment for biological samples. This addresses the critical need for reliable and efficient cryopreservation in the biomedical industry. The business model integrates hardware manufacturing with comprehensive service provisions, offering clients holistic solutions for their biobanking needs. Revenue is generated from selling this specialized equipment and providing full-process, one-stop services that include the planning, construction, management, and maintenance of biological sample and cell banks. Key clients include research hospitals, biomedical R&D enterprises, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), life science research institutions, and university medical schools.

OriginCell's product portfolio is designed to create a complete, automated, and intelligent solution for the entire bio-sample lifecycle. This includes automated storage systems for both ultra-low (-80°C) and deep cryogenic (-196°C) temperatures, covering both vapor-phase and liquid-phase liquid nitrogen environments. A standout product is the BSN series, a honeycomb-style automated storage system that ensures sample safety and minimizes cross-contamination. The company also provides auxiliary equipment such as controlled-rate freezers, automated thawing systems, intelligent transport robots (AGVs/RGVs), and a 5G-IoT remote management software platform called OBS-CybeBiobank5G-IoT for unmanned, intelligent sample bank operation. This integrated approach aims to standardize and automate cryopreservation, liberating scientists from manual labor and enhancing the quality and safety of stored biological samples.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2014
Headquarters
Tangshan City, China
Employees
2
Open positions
None listed
Dealroom signal
24.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b
Investment activity
1 company, latest Jan 2016
Capital deployed
$0
Preferred round
Unknown

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Aug 2022 $120M $480M Qiming Venture Partners · Quan Capital ↗
SERIES AOther financing May 2022 $56M $226M Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

OriginCell website traffic

Latest recorded traffic for OriginCell is 300 monthly website visits, down 14.3% over the last three months. OriginCell's team grew 0% over the past year.

Latest monthly visits300 3-month web change-14.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Employees 2 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Tangshan City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about OriginCell on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OriginCell’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.